Analysts Set Solid Biosciences Inc. (NASDAQ:SLDB) Price Target at $18.25

Shares of Solid Biosciences Inc. (NASDAQ:SLDB) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $18.25.

A number of equities analysts have issued reports on the company. Barclays increased their price target on Solid Biosciences from $8.00 to $21.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. William Blair reiterated an “outperform” rating on shares of Solid Biosciences in a research report on Thursday, March 28th. Citigroup assumed coverage on Solid Biosciences in a research report on Friday, March 15th. They set a “buy” rating and a $16.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Thursday, March 14th. Finally, Piper Sandler upgraded Solid Biosciences from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $8.00 to $20.00 in a research report on Thursday, March 14th.

Hedge Funds Weigh In On Solid Biosciences

An institutional investor recently bought a new position in Solid Biosciences stock. Vestal Point Capital LP purchased a new stake in Solid Biosciences Inc. (NASDAQ:SLDB) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 34,085 shares of the company’s stock, valued at approximately $209,000. Vestal Point Capital LP owned about 0.17% of Solid Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 81.46% of the company’s stock.

Solid Biosciences Stock Up 5.2 %

Solid Biosciences stock opened at $8.98 on Monday. The firm has a market cap of $339.71 million, a price-to-earnings ratio of -1.86 and a beta of 1.93. Solid Biosciences has a 52 week low of $1.81 and a 52 week high of $15.05. The business’s 50-day moving average price is $11.08 and its 200 day moving average price is $6.98. The company has a quick ratio of 8.94, a current ratio of 8.94 and a debt-to-equity ratio of 0.01.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.01. As a group, sell-side analysts anticipate that Solid Biosciences will post -2.64 earnings per share for the current year.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.